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Abstract
Background: Stereotactic body radiotherapy (SBRT) using flattening filter free (FFF)-techniques has been increasingly
applied during the last years. However, clinical studies investigating this emerging technique are still rare. Hence, we
analyzed toxicity and clinical outcome of pulmonary SBRT with FFF-techniques and performed dosimetric comparison
to conventional techniques using flattening filters (FF).
Materials and methods: Between 05/2014 and 06/2015, 56 consecutive patients with 61 pulmonary lesions were
treated with SBRT in FFF-mode. Central lesions received 8 × 7.5 Gy delivered to the conformally enclosing
80 %-isodose, while peripheral lesions were treated with 3 × 15 Gy, prescribed to the 65 %-isodose. Early and late
toxicity (after 6 months) as well as initial clinical outcomes were evaluated. Furthermore, [deleted] plan quality
and efficiency were evaluated by analyzing conformity, beam- on and total treatment delivery times in comparison to
plans with FF-dose application.
Results: Median follow-up time was 9.3 months (range 1.5–18.0 months). Early toxicity was low with only 5
patients (8.9 %) reporting CTCAE 2° or higher side-effects. Only one patient (1.8 %) was diagnosed with
radiation-induced pneumonitis CTCAE 3°, while 2 (3.6 %) patients suffered from pneumonitis CTCAE 2°. After
6 months, no toxicity greater than CTCAE 2° was reported. 1-year local progression-free survival, distant
progression-free survival and overall survival were 92.8 %, 78.0 %, and 94.4 %, respectively. While plan quality was
similar for FFF- and FF-plans in respect to conformity (p = 0.275), median beam-on time as well as total treatment
time were significantly reduced for SBRT in FFF-mode compared to FF-mode (p ≤ 0.001, p ≤ 0.001).
Conclusions: Patient treatment with SBRT using FFF-techniques is safe and provides promising clinical results
with only modest toxicity at significantly increased dose delivery speed.
Background
About 20 % of all patients diagnosed with early-stage
NSCLC or with oligometastasized tumors to the lung are
classified medically inoperable due to cardiopulmonary
comorbidities resulting in insufficient pulmonary function
[1–3]. Stereotactic body radiotherapy (SBRT) represents
the treatment of choice for these patients who often only
received best supportive care in former years. Indeed,
several recent studies about SBRT treatment for both,
early stage NSCLC and pulmonary metastases, showed
excellent local control rates of 78–96 %, which is con-
siderably better compared to historical data applying
conventional radiotherapy [4–9]. Interestingly, a recent
study of two pooled randomized trials even suggested
that SBRT treatment might even be an option for med-
ically operable patients diagnosed with stage I NSCLC
[10]. For oligometastastic patients, SBRT is discussed as
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a cytoreductive treatment option during systemic ther-
apy [11, 12]. Hence, SBRT is an optimal technique as it
offers the possibility of target dose escalation for maxi-
mizing tumor control, while sparing surrounding lung
tissue for minimizing toxicity.
However, SBRT delivery times often last long due to
high doses per fraction, limited dose rates, application of
multiple treatment beams and often usage of intensity-
modulated radiotherapy (IMRT) for further improving dose
conformality [13]. On the one hand, duration of SBRT
treatment is stressful for a frail elderly patient population
frequently suffering from severe cardiopulmonary comor-
bidities and who are commonly positioned within rigid and
uncomfortable full body casts. On the other hand, extended
treatment times might increase the risk of tumor displace-
ment due to intrafractional patient movement possibly
leading to extra imaging for position verification [14].
For accelerating delivery, the dose rate of a beam can
be increased by the removal of the flattening filter (FF)
resulting in a cone-shaped dose profile and up to a four-
fold higher dose rate in the center of the beam [15]. Fur-
thermore, using these flattening filter free (FFF)-techniques
a reduction of the out-of field dose is expected possibly
leading to decreased exposure to normal tissue [16, 17].
In Heidelberg, SBRT using FFF-techniques has been
clinically available for more than one year. This report
describes planning procedures and analyzes toxicity and
oncological outcome in 61 patients with pulmonary le-
sions treated in our department.
Materials and methods
Patients and pulmonary lesions
Patient characteristics are summarized in Table 1. Be-
tween May 2014 and June 2015, 56 patients with 61 pul-
monary lesions underwent SBRT using FFF-techniques
at the Department of Radiooncology at the University
Hospital in Heidelberg. All patients were diagnosed func-
tionally inoperable due to severe [deleted] pulmonary
comorbidities. Additionally, all patients underwent contrast-
enhanced CT scans for diagnosis, while patients with
limited stage NSCLC further received FDG-PET-CT
scans. The analysis was approved by the Ethics commit-
tee of the University Hospital Heidelberg (S-140/2016).
Written informed consent for publication of their images
was obtained from the respective patients. [deleted]
Planning and treatment features
Patients were immobilized in individually shaped body
casts and an additional abdominal compression device
was used on the upper abdomen for reduction of re-
spiratory tumor motion of lesions in the lower lobes. For
treatment planning, a thoracic CT scan with a slice thick-
ness of 3 mm was performed with the patient in treatment
position under shallow breathing. Additionally, to account
for respiratory motion, a 4-dimensional CT scan during
normal breathing was acquired.
Gross tumor volumes (GTV) were contoured on 3 mm
CT slices in several maximal-extension phases (including
maximal inspiration and expiration as well as the middle
breathing position) from the 4D-planning CT and
summed up to an internal target volume (ITV). To ac-
count for microscopic infiltration, a 5 mm safety margin
was added to form the clinical target volume (CTV). An
additional planning target volume (PTV) margin of 2 mm
Table 1 Patient characteristics of 56 patients with 61 pulmonary
lesions
Patients
Sex
Male 37 (66.1 %)
Female 19 (33.9 %)
Median age (range) 70.4 years (42.7–87.0)
≥ 70 years 31 (55.4 %)
< 70 years 25 (44.6 %)
Baseline Karnofsky Index
70 % (50–80 %)
Pulmonary function (median)
FEV1 (%) 62 % (27.8–120.4 %)
FEV1 (absolut) 1.7 l (0.83–4.38 l)
Smoking status
Active smokers 25 (44.6 %)
Former smokers 20 (35.8 %)
Never-smokers 6 (10.7 %)
Smoking status not known 5 (8.9 %)
Median packyears 43 (20–120)
Pulmonary lesions
TNM limited stage NSCLC patients
cT1cN0 14
cT2cN0 14
cT3cN0 0
cT4cN0 (further metastases in other lobe) 2
TNM locally advanced NSCLC patients
cT1cN1-3 4
cT2cN1-3 1
Pulmonary metastases – primary tumors
NSCLC 19
Breast cancer 2
Renal cell carcinoma 2
Prostate cancer 1
Sarcoma 1
Cancer of unkown primary 1
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was further added to account for positioning insecurities.
Central airway structures with a margin of 2 cm were
contoured to identify lesions beyond (“peripheral”) or
within (“central”) this structure and to determine the dose
prescribed. Central lesions were treated with 8 × 7.5 Gy
delivered to the conformally enclosing 80 %-isodose with
desired dose maxima of up to 75 Gy. Peripheral lesions
were planned to receive 3 × 15 Gy, prescribed to the
65 %-isodose with desired maximum doses of up to
69 Gy. Due to severe pulmonary comorbidities and
hence no other treatment options, five patients with lo-
cally advanced NSCLC with a small, peripheral primary
tumor were treated with SBRT to the primary tumor,
while the local lymph node metastases received conven-
tional radiotherapy (Table 1). These five patients add-
itionally received intensity-modulated radiotherapy to
the mediastinal and supraclavicular lymph node metas-
tases with median total dose of 60.0 Gy (range 54.0–
60.0 Gy) delivered in 27–30 fractions. Organs at risk
(OARs) and normal tissue constraints were adopted as
recently described by the Stereotactic Radiotherapy
Working Group of the German Society of Radiation
Oncology [18].
Delivery techniques comprised 3-D conventional (n = 30)
and VMAT (n = 31) radiotherapy using the FFF-mode.
Additional plans in FF-mode were calculated for all pa-
tients in the respective technique (3-D and VMAT). The
same number of fields or arcs was used for the correspond-
ing plans in FF-mode. For VMAT plans 1 arc (n = 18), 2
arcs (n = 11) and 3 arcs (n = 2) were used, while for 3-D-
conventional plans 6 fields (n = 3); 7 fields (n = 12), 8 fields
(n = 12) and 9 fields (n = 3) were applied. Plans were
designed and calculated using Oncentra (version 4.5).
[deleted] A Collapsed Cone (CC) algorithm was used
for dose calculation. All patients were treated with 6
MV FFF-plans using the Elekta Versa HD with a max-
imum dose rate of 1400 MU/min and 6 MV FF-plans
were calculated for comparison for each lesion. The
modified Paddick Conformity Index was applied for
comparison [19, 20]:
CI ¼ V
2
ptv;pi
V ptvV pi
;
where Vptv,pi is the partial volume of the PTV covered by
the prescribed isodose,Vptv is the planning target volume
and Vpi is the body volume of the patient covered by the
prescribed isodose. Hence, a score of 1.0 indicates
perfect conformity, while a score of less than 1 shows
worse conformity [19].
Beam-on time, as well as total treatment time, was
registered for all patients during each day of treatment.
Furthermore, beam-on and total treatment time were
also calculated for FF-plans for comparison.
Before the initial irradiation, image guidance was
performed by means of KV cone beam CT (CBCT). A
position verification was furthermore applied before
each fraction by orthogonal portal images being com-
pared with digitally reconstructed radiographs (DRR)
from the planning CT.
Outcome evaluation
All patients were seen for follow-up visits at the University
Hospital in Heidelberg and underwent a clinical examin-
ation and a CT or an X-ray scan of the thorax. The first
follow-up examination was performed 6–8 weeks after
radiotherapy with a CT scan and the following visits were
scheduled every 3 months for the first two years and after-
wards every 6 months. If no pathology was detected in the
CT scan, CT scans and X-rays scans were done alternately
every three months. Statistical comparisons were per-
formed with SPSS (version 20.0) using the non-parametric
Wilcoxon signed-rank test. Significance was noted for
two-tailed p-values of ≤ 0.05. Outcome was calculated
using the Kaplan-Meier-Method and treatment-related
toxicity was classified according to CTCAE v4.0. Local
control (LC) was defined as no progression of the tumor
within the treated area. Recurrences distant to the primary
pulmonary lesion in the same lobe were not classified
as local failure but as distant metastases. Overall and
progression-free survival as well as local and distant
progression-free survival was analyzed starting from the
end of radiotherapy. Furthermore, LC was calculated for
all pulmonary lesions (61 pulmonary lesions), while OS,
PFS and DPFS were analyzed for all patients (56 patients).
Results
Planning procedure and technical administration
In total, 61 pulmonary lesions were treated using SBRT
in the FFF-mode. While 25 lesions were classified as
central, 36 were peripheral lesions. [deleted] Mean PTV
was 58.2 ml (range: 6.1–99.8 ml).
To show comparability between FFF- and FF-techniques,
we generated both FFF- and FF-plans for all patients
and subjected them to comparative physical verification.
[deleted] The FFF-plans were non-inferior with a median
conformity index of 0.71 (range 0.42–0.92), while the
FF-plans showed a median conformity index of 0.69
(range 0.37–0.91) (p = 0.275).
As one advantage of SBRT treatment with the FFF-
technique is believed to be accelerated dose delivery, we
registered the treatment time per fraction starting from
the acquisition of CBCT and portal images until the
end of radiation for the 61 pulmonary lesions. While
the median treatment time for the FFF-technique plans
was found to be 8:17 min (range 5:02–13:54 min), treatment
with FF-plans lasted significantly longer with a median
time of 9:47 min (range 6:12–16:32 min) (p ≤ 0.001).
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Only focusing on beam-on time, treatment with FFF-
plans was found to be more than two times faster in
median compared to irradiation with FF-plans (1:29 vs.
3:24 min) (p ≤ 0.001).
Toxicity
Detailed patient and tumor characteristics’ are shown in
Table 1. All patients were classified functionally inoper-
able due to severe pulmonary disease. [deleted]
Table 2 shows mean doses for organs at risks (OARs):
for peripheral lesions treated with 3 × 15 Gy prescribed
to the 65 %-isodose and for central lesions treated with
8 × 7.5 Gy prescribed to the 80 %- isodose.
Data for early toxicity was available for all patients. In
general, early toxicity was low with only 5 patients (8.9 %)
suffering from CTCAE 2° or higher side-effects (Table 3).
Main acute side-effects were cough (25.0 %) and general
disorders/ fatigue (12.5 %). Radiation-induced pneumon-
itis was diagnosed in 7 patients (12.5 %) after 3 months,
while pneumonitis CTCAE 2° and 3° was only detected in
one patient each during the first 3 months (Table 3).
The patient diagnosed with radiation-induced pneumon-
itis CTCAE 3° had already suffered from an oxygen-
dependent COPD (GOLD IV) before SBRT. Treatment
comprised increased oxygen therapy and oral steroids
which led to a permanent remission of the clinical and
radiological symptoms and changes.
Only a subset of 43 patients (76.8 %) with a median
follow-up time of 10.8 months (range 5.3–18.0 months)
was available for late toxicity evaluation after 6 months.
No toxicity greater than CTCAE 2° was reported (Table 4).
However, radiation-induced pneumonitis rate increased
by number but not by toxicity grade with 15 patients
(34.9 %) suffering from pneumonitis CTCAE 1° and 3
patients (7 %) from CTCAE 2°. Figure 1 and 2 illustrate
treatment planning and radiation-induced treatment
changes for two exemplary patients.
Survival and local control
Median follow-up time was 9.3 months (range 1.5–
18.0 months). 1-year OS and 1-year PFS were 94.4 %
and 77.6 %, respectively. OS was significantly worse for
patients with pulmonary metastases compared to pri-
mary NSCLC patients (p = 0.029). During follow-up
time, only two patients developed local progression
resulting in a 1-year LPFS of 92.8 % (Fig. 3). These two
patients were also diagnosed with distant metastases at
the same time. LPFS was not significantly different for
primary NSCLC patients and patients with pulmonary
metastases. Major failure pattern was distant with 1-year
DPFS of 78.0 %. In total, 15 patients (26.8 %) suffered
from distant progression during follow-up time. Patients
with locally advanced NSCLC and patients with pulmon-
ary metastases showed a strong tendency towards a higher
risk of distant failure compared to early-stage NSCLC pa-
tients (p = 0.07). Distant relapses occurred in lungs (n = 9),
brain (n = 4), liver (n = 2) and other organs (n = 4). Fur-
thermore, OS, PFS as well as LPFS and DPFS were not
significantly influenced by Karnofsky performance score,
pulmonary function, toxicity, lesion size and localization
Table 2 Summary of dose volume histogram doses for organs
at risks
Organs at risk Peripheral lesions Central lesions
Mean dose ipsilateral lung (Gy) 4.9 11.1
Mean dose contralateral lung (Gy) 0.9 2.2
Mean dose both lungs (Gy) 2.9 6.7
D2%-dose spinal cord (Gy) 6.9 12.5
D2%-dose central airways (Gy) 5.8 19.4
D2%-dose esophagus (Gy) 8.4 17.3
Dose in Gy shown; D2%: dose received by at least 2 % of the volume
Table 3 observed acute side-effects classified according to
Common Terminology Criteria Adverse Events, version 4.0
CTCAE, version 4.0
Component and disorders 0 1 2 3 4
General disorder, fatigue 49 (87.5) 7 (12.5) 0 (0) 0 (0)
Cough 42 (75.0) 11 (19.6) 2 (3.6) 1 (1.8)
Dyspnea 55 (98.2) 1 (1.8) 0 (0) 0 (0) 0 (0)
Pneumonitis 49 (87.5) 5 (8.9) 1 (1.8) 1 (1.8) 0(0)
Esophagitis 54 (96.4) 2 (3.6) 0 (0) 0 (0) 0 (0)
Rib fractures 56 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Chest wall pain 53 (94.6) 3 (5.4) 0 (0) 0 (0) 0 (0)
Pleural and pericardial
effusion
56 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Abbreviation: CTCAE common terminology criteria adverse events
Data presented as number of treated patients, with percentages in parentheses
Table 4 observed side-effects classified according to Common
Terminology Criteria Adverse Events, version 4.0, during short-term
follow-up (6 months after SBRT)
CTCAE, version 4.0
Component and disorders 0 1 2 3 4
General disorder, fatigue 43 (100) 0 (0) 0 (0) 0 (0)
Cough 37(88.4) 4(9.3) 1(2.3) 0 (0)
Dyspnea 42 (97.7) 1 (2.3) 0 (0) 0 (0) 0 (0)
Pneumonitis 25 (58.1) 15 (34.9) 3(7.0) 0(0)
Esophagitis 42 (97.7) 1 (2.3) 0 (0) 0 (0) 0 (0)
Rib fractures 43 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Chest wall pain 43 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Pleural and pericardial effusion 43 (100) 0 (0) 0 (0) 0 (0) 0 (0)
Abbreviation: CTCAE common terminology criteria adverse events
Follow-up after 6 months was only available for 43 patients. Data presented as
numbers of treated lesions, with percentages in parentheses
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Fig. 1 Treatment planning with dose-volume-histogram (PTV and OARs) and follow-up CT-scans for a central pulmonary tumor. Continuous
tumor shrinkage with only rare signs of fibrosis
Fig. 2 Treatment planning with dose-volume-histogram (PTV and OARs) and follow-up CT-scans for a peripheral pulmonary tumor. Radiation
associated imaging changes: increasing perilesional, ground glass opacity leading to fibrosis
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(central vs. peripheral) as well as irradiation dose in bio-
logical effective dose (BED).
Discussion
In the current study, SBRT treatment in FFF-mode was
found to be effective and safe while reducing beam-on
time to more than half compared to treatment in FF-
mode.
Up to now, there are only few and heterogeneous
studies investigating toxicity and outcome of SBRT with
FFF-beams for lung tumors [21–24]. Most of these stud-
ies not only focus on SBRT for pulmonary lesions, but
include various other tumors and locations treated with
SBRT. Furthermore, applied doses and fractionation
schemes are not homogeneous and often vary strongly.
Hence, we report our initial experiences with the clinical
implementation of SBRT using FFF-beams for 61 pul-
monary lesions treated with homogeneous concepts.
Performing comparative plan analysis, we detected
similar conformity indices for FFF-plans and FF-plans
(p = 0.275). To our knowledge, there is only one further
study which showed comparable plan quality for lung
SBRT [25]. Furthermore, comparing treatment time for
radiotherapy plans in FFF-mode to FF-plans in the re-
spective technique, we detected a significant reduction.
In detail, beam-on time was even reduced to more than
half in median when comparing plans in FFF-mode to
FF-technique. Others groups also confirmed accelerated
dose delivery using the FFF-technique [21, 22, 26].
Although median follow-up time was rather short with
9.3 months, we detected 1-year local progression-free
and overall survival rates of 92.8 % and 94.4 %, respect-
ively. Recently, Stieb and colleagues described similar re-
sults investigating local progression-free and overall
survival after SBRT treatment using FFF-techniques [24].
Biological concerns have been reported that SBRT
applying FFF-beams might increase toxicity [27, 28].
There is an ongoing debate whether the applied dose
rate directly affects cell survival and perhaps even toxicity.
Recently, Lohse et al. demonstrated that irradiation of
glioblastoma cell lines using FFF-beams was more efficient
in reducing cell survival than the standard flattened beam.
Additionally, this anti-tumor cell effect was more
dependent on dose per pulse rate than on delivery time
and became more evident with higher single doses
[27]. Hence, increased toxicity after SBRT treatment in
FFF-mode was discussed. However, Sorensen et al. and
other groups did not detect any effect of instantaneous
dose rate on cell survival applying high-dose rate FFF
irradiation [29–31].
Despite the discussed altered radiobiology, we detected
comparably low toxicity in our analysis. Only one patient
(1.8 %) suffered from toxicity CTCAE 3°, while no tox-
icity CTCAE 4° and 5° were reported. Similar results were
reported by Navarria et al. who analyzed 46 pulmonary le-
sions for early toxicity after SBRT applying FFF-beams
[21]. There is only one study which reported comparably
higher toxicity after SBRT in FFF-mode: Prendergast and
colleagues described three patients with pulmonary
toxicity CTCAE 3° and one patient each with CTCAE
4° and 5° pulmonary events analyzing 49 patients treated
with SBRT for lung malignancies [28]. In this study, no
comparison between FFF- and FF-mode was performed
and higher biological effective doses were used in 29 % of
the patients compared to our study [28]. In general, higher
biological effective doses are expected to cause higher tox-
icity. Furthermore, doses and fractionation schemes are
routinely adjusted to tumor location, as excessive toxicity
after SBRT was reported for central tumors [32]. Hence,
the different applied dose and fractionation schemes in
the study of Pendergast et al. might explain the detected
increased toxicity. Up to now, there is no convincing clin-
ical evidence for the discussed increased toxicity for SBRT
in FFF-mode. [deleted]
O
ve
ra
ll 
su
rv
iv
al
 (
%
) 
Follow-up (months)
L
o
ca
lp
ro
g
re
ss
io
in
-f
re
e
su
rv
iv
al
(%
)
BA
Follow-up (months)
Fig. 3 Overall survival (a) and local progression-free survival (b) after SBRT in FFF-mode
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Despite the mentioned radiobiological concerns in
respect to dose rate and toxicity, treatment applying
FFF-plans is known to provide several dosimetric advan-
tages compared to conventional unflattened photon beam
therapy. Removing the flattening filter leads to a reduction
of out-of field dose due to reduced head scatter, leaf trans-
mission and lower dose outside the field edge [15, 16, 33].
Hence, sparing of the OARs should be more effective and
lower toxicity rates are expected. Furthermore, Cash-
more and colleagues even suggested that irradiation in
FFF-mode might even reduce the risk of secondary ma-
lignancies by lowering doses by up to 70 % [34]. Limita-
tions to our analysis were the relatively short follow-up
time and the retrospective design of the study. Toxicity
data was only available for the first 6 months for some
patients and therefore later side-effects could only be
evaluated for a subset of patients.
Conclusions
In this retrospective analysis, we demonstrated that SBRT
using FFF-techniques was time efficient while providing
similar plan quality. Furthermore, early clinical results
were promising with only modest toxicity.
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